Outlier [Study As­sess­ment]

posted by NK – India, 2023-06-27 05:57 (688 d 16:14 ago) – Posting: # 23616
Views: 3,019

Dear All,

Please give your valuable inputs.

We have performed 2x2 fasting BE pivotal study for USFDA after seeing pilot study results.

We've noted following from pivotal study data,How to handle this subject’s data? Outlier? Can the regulatory accept the based on Cmax and AUC0-t results?

Can we select the time point manually for Kel calculation instead of best fit method by the tool?

Thanks & Regards
NK


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
121 visitors (0 registered, 121 guests [including 34 identified bots]).
Forum time: 22:11 CEST (Europe/Vienna)

Don’t undertake a project
unless it’s manifestly important
and nearly impossible.    Edwin H. Land

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5